Mevion Single Room Proton Therapy System Treats more than 520 Patients in Two Years

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

“The MEVION S250 system’s direct beam technology, efficient clinical workflow and high system availability, combined with the collaboration and established treatment protocols of existing proton centers have made this exciting milestone possible,” said Scot Ackerman, MD, medical director of Ackerman Cancer Center. “We are able to treat a diverse set of cancers with proton therapy including breast, head and neck, lung, prostate, and others. Patients have come to us from all across the United States, Canada, and Central America for treatment. And our team is proud to be able to partner with Mevion to provide accessible proton therapy to our patients.”

In a major milestone for the proton therapy industry, the MEVION S250 Proton Therapy System at Ackerman Cancer Center (ACC) in Jacksonville, Fla., has treated 526 patients with proton therapy just 24 months after first patient treatment. This is the highest number of proton therapy patients ever treated in two years in a single room, and exceeds the two-year patient volume of many larger three-, four- and five-room systems.

“The MEVION S250 system’s direct beam technology, efficient clinical workflow and high system availability, combined with the collaboration and established treatment protocols of existing proton centers have made this exciting milestone possible,” said Scot Ackerman, MD, medical director of Ackerman Cancer Center. “We are able to treat a diverse set of cancers with proton therapy including breast, head and neck, lung, prostate, and others. Patients have come to us from all across the United States, Canada, and Central America for treatment. And our team is proud to be able to partner with Mevion to provide accessible proton therapy to our patients.”

Soon after it opened on April 30, 2015, the MEVION S250 system at Ackerman Cancer Center achieved the fastest per-room patient ramp-up in the history of proton therapy. It now treats, on average, 40 proton therapy patients per day during a 12-hour shift. The high throughput is due to the MEVION S250 system’s efficient, linac-like workflow, low maintenance requirements, and industry-leading uptime, demonstrating that compact proton therapy can be a viable option for any size cancer center. Based on the success of its first Mevion unit, ACC plans to install a second system, a MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning technology.

“The fact that Mevion is helping ACC provide so many patients with the cancer care they need validates our mission of delivering the most advanced, accessible, and financially viable proton therapy system available today,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “526 patients in two years of clinical operation would be a huge achievement for a multi-room center, and ACC has now achieved that goal with a single room.”

Proton therapy provides targeted radiation treatment for many types of cancer, significantly reducing the dose of radiation to healthy tissue by as much as a factor of three, while still maintaining high conformance to the treatment target. The National Comprehensive Cancer Network (NCCN) recently updated its clinical practice guidelines to add proton therapy as an appropriate therapy in the management of several additional critical indications including esophageal carcinomas, head and neck, hepatobiliary and non-small-cell lung carcinomas.

Mevion invented the compact proton therapy system to help increase access to this valuable therapy. Mevion currently has more compact systems treating patients than any other proton therapy manufacturer, with 100% of Mevion clinical sites achieving 100% of their financial objectives in the first year.

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.